Skip to main content

Table 1 Characteristics of included studies

From: Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis

Study

Year

Country

Study design

Population

Age, yrs

Male, n

Mean time intervala

Blindb

Reference test

Index measured using CMR

Field strength

Hosch et al.

2007

Germany

PC

19 with newly diagnosed CA and 9 patients with systemic amyloidosis but without CA and 10 healthy, age-matched control

59 ± 6.1

14

NA

Y

EMB

T1 and T2 RT

1.5 T

Vogelsberg et al.

2008

Germany

NA

33 subjects with suspected CA

64 ± 13

NA

Same day

Y

EMB

Amyloid LGE pattern

1.5 T

Austin et al.

2009

USA

RC

47 subjects with suspected CA

62

33

24–48 h

N

EMB

LGE; DHE

1.5 T

Ruberg et al.

2009

USA

PC

28 patients with systemic AL amyloidosis

62 ± 11

20

NA

Y

EMB or clinical criteria

LGE

1.5 T

Karamitsos et al.

2013

UK/Canada

NA

53 patients with systemic (primary) AL amyloidosis and 17 patients with aortic stenosis and 36 normal volunteers

63 ± 10c

69

NA

Y

Echocardiography and clinical features

Noncontrast T1 mapping; LGE

1.5 T

Aquaro et al.

2014

Italy

PC

59 patients with a previous diagnosis of systemic AL amyloidosis and 20 healthy control subjects

69 ± 10

36

Same day

Y

Echocardiographic criteria and/or ECG criteria or EMB

SID; conventional LGE

1.5 T

White et al.

2014

USA

PC

90 patients with suspected CA and 64 hypertensive patients with LVH

62 ± 13

52

NA

Y

EMB

LGE pattern:

Global HE

1.5 T

  1. AL amyloid light-chain, CA cardiac amyloidosis, DHE delayed hyper-enhancement, ECG echocardiography, HE hyperenhancement, EMB endomyocardial biopsy, LGE late gadolinium enhancement, LVH left ventricular hypertrophy, N no, NA not available, PC prospective cohort, RC retrospective cohort, RT relaxation times, SID signal intensity decay
  2. aTime interval between reference tests and cardiac magnetic resonance
  3. bThe CMR results were interpreted blind to the results of the reference tests or the reference tests were performed without knowing the results of cardiac magnetic resonance
  4. cAmyloid patients with definite cardiac involvement